Jennifer S. ArmisteadIsabelle MorlaisDerrick K. MathiasJuliette G. JardimJaimy JoyArthur FridmanAdam C. FinnefrockAnsu BagchiMagdalena PlebanskiDiana G. ScorpioThomas S. ChurcherNatalie A. BorgJetsumon SattabongkotRhoel R. DinglasanaJohns Hopkins Bloomberg School of Public HealthInstitut de Recherche pour le Developpement CameroonMerck Research LaboratoriesMonash UniversityThe Johns Hopkins School of MedicineImperial College LondonMahidol UniversityWalter and Eliza Hall Institute of Medical Research2018-11-092018-11-092014-02-01Infection and Immunity. Vol.82, No.2 (2014), 818-82910985522001995672-s2.0-84893008833https://repository.li.mahidol.ac.th/handle/123456789/33998Malaria transmission-blocking vaccines (TBVs) represent a promising approach for the elimination and eradication of this disease. AnAPN1 is a lead TBV candidate that targets a surface antigen on the midgut of the obligate vector of the Plasmodium parasite, the Anopheles mosquito. In this study, we demonstrated that antibodies targeting AnAPN1 block transmission of Plasmodium falciparum and Plasmodium vivax across distantly related anopheline species in countries to which malaria is endemic. Using a biochemical and immunological approach, we determined that the mechanism of action for this phenomenon stems from antibody recognition of a single protective epitope on AnAPN1, which we found to be immunogenic in murine and nonhuman primate models and highly conserved among anophelines. These data indicate that AnAPN1 meets the established target product profile for TBVs and suggest a potential key role for an AnAPN1-based panmalaria TBV in the effort to eradicate malaria.© 2014, American Society for Microbiology.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1128/IAI.01222-13